{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 42,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 42,
  "notes": "Includes detailed patient enrollment table by dose cohort and trial objectives.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/17",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.39,
        "y": 0.67
      },
      "kind": "disclaimer",
      "text": "1G, 1st generation ALK TKI... Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6fd528a-e09b-4fa9-b789-56458418001b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "list",
      "text": "PATIENT POPULATION: Advanced solid tumors harboring ALK fusion or activating mutation; Patients with NSCLC: ≥ 1 prior 2G or 3G ALK TKI; ≤ 2 prior chemotherapies/immunotherapies; Excluded: concurrent oncogenic drivers; Evaluable but non-measurable disease allowed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1852f272-a430-4e23-b26f-5432c555ae76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.06,
        "y": 0.68
      },
      "kind": "list",
      "text": "PHASE 1 OBJECTIVES: Selection of RP2D and, if applicable, MTD (primary); Overall safety and tolerability; PK characterization; Preliminary antitumor activity; Intracranial activity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7110f16-8edb-43a1-a5f8-2ed8302e72ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.06,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "PHASE 1 DOSE-ESCALATION. Phase 1 enrollment completed February 2024: Updated data to be presented at a medical meeting in 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f081c82a-a1a2-40cb-997a-eb1697ba7025",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.39,
        "y": 0.28
      },
      "kind": "table",
      "text": "Enrollment table showing NVL-655 Dose Cohorts (BOIN, Expansion, All-Treated, NSCLC Response-Evaluable) across dose levels (15mg to 200mg QD).",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52b57cb7-f04e-4a09-b8d4-ba250a8acef6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.27,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKove-1: A Global First-in-Human Phase 1/2 Clinical Trial of NVL-655 in Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95b7d852-d90f-4dab-8074-13f5074f44f8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "2e9cef62-0280-4fff-98c0-e39b220e0cd1",
      "evidence": "table/data: Enrollment table showing NVL-655 Dose Cohorts (BOIN, Expansion, All-Treated, NSCLC Response-Evaluable) across dose levels (15mg to 200mg QD).",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 36,
      "from": 17,
      "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck presents traction and clinical trial data from slides 17 to 36",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "768b9693-f057-40a9-8283-be0c1cfc71ac",
      "evidence": "The deck presents data on the cost of inaction for cancer patients and how Nuvalent's solution addresses this",
      "position": 1,
      "objective": "What is the cost of inaction for cancer patients and how does Nuvalent's solution address this?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}